Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 9 of 19 for:    arog

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02400281
Recruitment Status : Active, not recruiting
First Posted : March 27, 2015
Last Update Posted : January 7, 2020
Information provided by (Responsible Party):
Arog Pharmaceuticals, Inc.

Brief Summary:
This is an open label, two-arm, Phase I-II trial, non-randomized. Arm 1: crenolanib with standard chemotherapy (Idarubicin/Cytarabine, MEC;Mitoxantrone/Etoposide/Cytarabine, FLAG-Ida: Fludarabine/Cytarabine/G-CSF/Idarubicin) Arm 2: crenolanib with 5-azacitidine

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Drug: Crenolanib besylate Drug: Idarubicin Drug: Cytarabine Drug: Azacytidine Drug: Mitoxantrone Drug: Etoposide Drug: Fludarabine Drug: G-CSF Phase 1 Phase 2

Detailed Description:

For each arm:

The phase I with dose-limiting toxicity (DLT) determination will use 3+3 design.

Phase II total of 52 patients (26 per arm) will be treated at established phase I dose.

Enrollment to be simultaneous to each arm.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 88 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I-II Study of Crenolanib Combined With Standard Salvage Chemotherapy, and Crenolanib Combined With 5-Azacitidine in Acute Myeloid Leukemia Patients With FLT3 Activating Mutations
Study Start Date : September 2015
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : April 2020

Arm Intervention/treatment
Experimental: Arm 1 crenolanib besylate combination
Arm 1 patients will receive crenolanib besylate, combined with standard chemotherapy (Idarubicin/Cytarabine, MEC;Mitoxantrone/Etoposide/Cytarabine, FLAG-Ida: Fludarabine/Cytarabine/G-CSF/Idarubicin
Drug: Crenolanib besylate
Other Name: CP-868,596-26

Drug: Idarubicin
Other Name: 4-demethoxydaunorubicin

Drug: Cytarabine
Other Name: cytosine arabinoside

Drug: Mitoxantrone
Other Name: Novantrone

Drug: Etoposide
Other Name: etoposide phosphate

Drug: Fludarabine
Other Name: Fludarabine phosphate

Drug: G-CSF
Experimental: Arm 2 crenolanib besylate combination
Arm 2 patients will receive crenolanib besylate and azacytidine.
Drug: Crenolanib besylate
Other Name: CP-868,596-26

Drug: Azacytidine
Other Name: 5-azacytidine

Primary Outcome Measures :
  1. Dose-limiting toxicities of crenolanib besylate combination therapy [ Time Frame: 6 months ]
  2. Response rate of crenolanib besylate combination therapy [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Duration of response [ Time Frame: 2 years ]
  2. Progression free survival [ Time Frame: 2 years ]
  3. Overall survival [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Confirmed diagnosis of refractory/relapsed AML or high-risk MDS

    • Arm 1: Subjects must have received at least one prior therapy and a maximum of three prior therapies
    • Arm 2: Subjects must have received at least one prior therapy and a maximum of three prior therapies. No prior treatment with 5-Azacitidine is allowed in this arm.
  2. FLT3 mutation positive (ITD, TKD or other)
  3. ECOG PS 0-2
  4. Adequate liver and renal function
  5. Negative pregnancy test
  6. Extramedullary leukemia allowed except CNS disease

Exclusion Criteria:

  • Arm 1 and 2 Exclusion:

    1. <5% blasts in marrow or blood at time of screening
    2. Active HIV, hepatitis B or C
    3. CNS leukemia
    4. Clinically significant GVHD or organ dysfunction where chemotherapy specified by protocol cannot be given
    5. Patient with AML-M3 (APL)
    6. Pre-existing liver diseases (i.e. cirrhosis, chronic hepatitis B or C, nonalcoholic steatohepatitis, sclerosing cholangitis)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02400281

Layout table for location information
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Arog Pharmaceuticals, Inc.
Layout table for investigator information
Principal Investigator: Jorge Cortes, MD M.D. Anderson Cancer Center

Layout table for additonal information
Responsible Party: Arog Pharmaceuticals, Inc. Identifier: NCT02400281    
Other Study ID Numbers: ARO-010
First Posted: March 27, 2015    Key Record Dates
Last Update Posted: January 7, 2020
Last Verified: January 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Fludarabine phosphate
Etoposide phosphate
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antiviral Agents
Anti-Infective Agents
Antineoplastic Agents, Phytogenic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Sensory System Agents
Peripheral Nervous System Agents